Introduction: Numerous previous studies investigated the impact of medical training settings on outcomes of hospitalized patients. Percutaneous paracentesis is frequently a bed-side procedure that is commonly performed by healthcare providers in training. However, impact of teaching hospital status on outcomes of percutaneous paracentesis to the best of our knowledge have never been studied before. Methods: Hospitalized patients who underwent percutaneous paracentesis were identified from the National Inpatient Sample database 2016 to 2019 across United States teaching and non-teaching hospitals. Univariate and Multivariate logistic regression analysis was performed to determine the risk difference in mortality, postprocedural outcomes and healthcare resources utilization in the studied groups. Multivariate logistic analysis was performed using STATA software and results were adjusted for patient and hospital characteristics and comorbidities. Results: Among 1,031,485 admitted adults’ patients who underwent percutaneous paracentesis, 791,700 (76.8%) subjects were managed at US teaching hospitals, while 239,785 (23.2%) were admitted to non-teaching hospitals (Figure). Patients baseline comorbidities are listed in Table. Inpatient mortality rates (Figure) were significantly higher in individual undergoing paracentesis at US teaching hospitals (aOR 1.29, 95% CI 1.23 - 1.35, p< 0.001) compared to non-teaching hospitals. Similarly, higher risk of procedural complications including hemoperitoneum (aOR 1.90, 95% CI 1.65 – 2.20, p< 0.001), hollow viscus perforation (aOR 1.97, 95% CI 1.54 - 2.51, p< 0.001) and vessel injury/laceration (aOR 15.3, 95% CI 2.12 - 110.2, p=0.007) were noticed in study group when compared to controls. Furthermore, hospital teaching status was associated with prolonged mean length of stay (9.33 days vs 7.42 days, adjusted mean difference (aMD) 1.81, 95% CI 1.68 - 1.94, p< 0.001) and increased charge of care (106,014$ vs 80,493$, aMD 24,926$, 95% CI 21,617$ – 28,235$, p < 0.001). Conclusion: Hospitalized patients undergoing paracentesis in US teaching hospitals have increased risk of mortality, postprocedural complications, prolonged length of stay and increased charge of care when compared to non-teaching hospitals. As the first study to answer this question, further studies are needed to confirm our findings and the relationship impact of new trainees involved in the care of ascites patients on the outcomes of those undergoing paracentesis. Table 1. - Baseline characteristics and comorbidities of patients managed with percutaneous paracentesis in US teaching and non-teaching hospitals Paracentesis %, NO. Teaching %, NO. Non-teaching %, NO. P-value (100,0) 1,031,485 (76.8) 791,700 (23.2) 239,785 Patient’s characteristics Age, mean years 59.3 59.0 60.6 < 0.001 Female 43.8 (451790) 43.9 (347556) 43.3 (103827) 0.028 Racial distribution White 66.0 (680780) 64.23 (508509) 72.15 (173005) < 0.001 Black 12.6 (129967) 13.8 (109255) 8.70 (20861) < 0.001 Hispanic 14.4 (148534) 14.7 (116380) 13.3 (31891) < 0.001 Others 2.75 (28366) 2.88 (22801) 2.32 (5563) < 0.001 Insurance type Medicaid 46.1 (475515) 45.2 (357848) 49.2 (117974) < 0.001 Medicare 23.6 (243430) 23.9 (189216) 22.8 (54671) < 0.001 Private 24.9 (256840) 25.7 (203467) 22.3 (53472) < 0.001 Uninsured 5.33 (54978) 5.20 (41168) 5.75 (13788) < 0.001 Charlson comorbidity index score 1 9.47 (97682) 9.09 (71966) 10.7 (25657) < 0.001 2 7.89 (81384) 7.71 (61040) 8.47 (20310) < 0.001 ≥3 75.2 (775677) 75.6 (598525) 74.0 (177441) < 0.001 Median annual income, us$ 1–43,999 31.0 (319760) 30.8 (243844) 31.7 (76012) < 0.001 44,000–55,999 26.0 (268186) 25.1 (198717) 28.9 (69298) < 0.001 56,000–73,999 23.9 (246525) 24.1 (190800) 23.0 (55151) < 0.001 ≥74,000 19.1 (197014) 20.0 (158340) 16.3 (39085) < 0.001 Hospital characteristics Hospital region Northeast 18.5 (190825) 20.7 (163882) 11.2 (26856) < 0.001 Midwest 21.7 (223832) 22.8 (180508) 18.2 (43641) < 0.001 South 38.0 (391964) 36.0 (285012) 44.6 (106944) < 0.001 West 21.8 (224864) 20.5 (162299) 26.0 (62344) < 0.001 Hospital bed size Small 15.8 (162975) 17.5 (138548) 10.3 (24698) < 0.001 Medium 27.4 (282627) 27.0 (213759) 28.5 (68339) < 0.001 Large 56.8 (585883) 55.5 (439394) 61.2 (146748) < 0.001 Comorbidities Hypertension 27.7 (285721) 27.6 (218509) 28.1 (67380) 0.066 Diabetes mellitus 31.8 (328012) 31.5 (249386) 32.9 (78889) < 0.001 Smoking history 39.9 (411563) 39.6 (313513) 40.9 (98072) 0.001 Hyperlipidemia 22.9 (236210) 22.7 (179716) 23.3 (55870) 0.039 Obesity 12.1 (124810) 12.1 (95796) 12.2 (29254) 0.745 Chronic kidney disease 28.1 (289847) 27.8 (220093) 29.1 (69777) < 0.001 Coronary artery disease 15.4 (158849) 15.1 (119547) 16.5 (39565) < 0.001 Peripheral vascular disease 1.87 (19289) 1.80 (14251) 2.30 (5515) < 0.001 Chronic obstructive lung disease 13.5 (139250) 12.7 (100546) 16.3 (39085) < 0.001 Human immunodeficiency virus 0.60 (6189) 0.70 (5542) 0.40 (959) < 0.001 Congestive heart failure 19.0 (195982) 18.8 (148840) 20.0 (47957) < 0.001 Nephrotic syndrome 0.20 (2063) 0.22 (1742) 0.15 (360) 0.002 Chronic liver disease 66.0 (680780) 65.2 (516188) 68.7 (164732) < 0.001 Malignancy 12.5 (128936) 12.8 (101338) 11.6 (27815) < 0.001 Pancreatitis 4.11 (42394) 4.10 (32460) 3.90 (9352) 0.028 Figure 1.: Flow diagram of study sample.